Integra Lifesciences Holdings Corp（IART）股票分析IARTIntegra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Integra Lifesciences Holdings Corp (IART) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $13.21, which is below the adjusted analyst price target of $15. Additionally, the RSI is at 36.99, indicating that the stock is nearing oversold territory but has not yet shown a strong reversal signal. The company has faced challenges, including a significant net income loss of $484 million in Q2 2025, which raises concerns about its profitability moving forward. However, the gross margin remains relatively healthy at 54.90% in Q2 2026, suggesting some operational efficiency. The main risk is the company's high debt-to-equity ratio of 179.45%, which could limit financial flexibility and growth opportunities.

15 analysts cover IART: 9 rate it Buy, 6 Hold and 0 Sell. The average price target is 12.33.